MiRNA-based Therapeutic Strategy in Lung Cancer

Title:MiRNA-based Therapeutic Strategy in Lung Cancer

Volume: 23 Issue: 39

Author(s): Guang Li, Jing Fang, Ying Wang, Hu Wang*Cheng-Cao Sun*

Affiliation:

• Department of Oncology, Wuhan Fifth Hospital, JiangHan University, 430050 Wuhan, Hubei,China

• Department of Occupational and Environmental Health, School of Public Health, Wuhan University, 430071 Wuhan, Hubei,China

Keywords: miRNA, lung cancer, non-small cell lung cancer, adenocarcinoma, resistance, therapeutic strategy.

Abstract: Lung cancer is one of the most common malignant tumors in the world. Although advanced therapies have been applied for the treatment of lung cancer, the prolongation of overall survival is limited due to treatment resistance. MicroRNAs (miRNAs) are a class of small non-coding, endogenous RNA molecules (about 19-23 nucleotides in length), which could regulate numerous human genes and play key roles in a variety of diseases. MiRNAs are dysregulated in lung cancer and participate in tumor initiation, development and drug resistance. Recent studies showed a new therapeutic strategy for cancer therapy based on miRNAs. In this review, we briefly summarize one classic pathway of miRNAs in lung cancer, and discuss a new miRNA-based therapeutic strategy to manage lung cancer.

Cite this article as:

Li Guang , Fang Jing, Wang Ying, Wang Hu *, Sun Cheng-Cao*, MiRNA-based Therapeutic Strategy in Lung Cancer, Current Pharmaceutical Design 2017; 23 (39) . https://dx.doi.org/10.2174/1381612823666170725141954